In partership with SLAS logo_200px-1
Ignite theater speaker images_200px-2

Join DDW at SLAS2024 in Boston on 5 and 6 February 2024 for its ‘Innovation & technology: from lab to patient’, track sponsored by Integra Biosciences and Hamamatsu Corporation. It will take place in the SLAS Ignite Theater.

Inspired by the event theme of ‘Innovation at Every Turn’, the DDW-curated track will present leading research and case studies from industry experts in the pharmaceutical, biopharmaceutical and biotech industries on how technology is innovating from bench to bedside, lab to patient.

The first speaker in the DDW track will be Dipanwita Das, CEO of Sorcero, answering the question ‘Is pharma’s commercial model dying?’ on Monday 5 February at 11.30am.

She will be followed by Andrea Bortolato, Director of Drug Discovery at SandboxAQ, at 3pm, who will speak on ‘Combining physics-based methods with AI solutions to maximise the probability of success and speed of drug discovery and development’.

At 3.30pm, Simon Bushell, SVP of Molecular Discovery at Entact Bio, will share his experience on ‘Proximity-inducing drugs: Using technological innovation to build the next generation of medicine’.

On Tuesday 6 February at 11.30am, attendees will hear on the topic ‘Structural vaccinology for influenza’ from Masaru Kanekiyo, Chief of Molecular Immunoengineering Section of the Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID).

Isaac Bentwich, Founder and CEO of Quris-AI, named one of the World’s Most Innovative Companies for 2023, will discuss ‘How AI and patient-on-chip are improving drug discovery and development’ at 3pm.

‘Accelerating biotherapeutics development through technology platforms’ will be addressed by Anubhav Tripathi, Professor of Medical Science and Engineering at Brown University at 3.30pm.

Only registered attendees of SLAS2024 will be able to attend. 

Track Co-Sponsors Integra Biosciences and Hammatsu


There are limited free places available so register your interest here.